source
- Roche signs $2.5 billion deal with Hanmi for experimental obesity drug targeting muscle lossRoche's Genentech unit has agreed to acquire global rights (outside South Korea) to Hanmi's clinical-stage urocortin-2 analog, HM17321, as part of a deal valued up to $2.5 billion. The agreement i…
- Study finds SNAP soda bans cut purchases by 12% among beneficiariesA new study shows that purchases of soda fell by roughly 12% among people receiving Supplemental Nutrition Assistance Program benefits after the bans on soda and candy took effect in ten states. Th…